During a scientific conference on Tuesday, Johnson & Johnson (NYSE:JNJ) announced positive results from a human proof-of-concept trial with relapsed multiple myeloma patients and teclistamab, the bispecific antibody formerly known as JNJ-5957. At the American Society of Clinical Oncology's conference, which was held virtually, J&J presented interim results that strongly suggest teclistamab can make a significant difference for patients who have relapsed after receiving between two and 14 lines of treatment.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,